21:41 , Nov 30, 2017 |  BC Innovations  |  Strategy

Doctors in the house

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous GSK3196165: Phase II started

GlaxoSmithKline began a double-blind, placebo-controlled, European Phase II trial to evaluate 8 injections of subcutaneous GSK3196165 over 12 weeks in 40 patients. GSK has exclusive, worldwide rights to the compound from MorphoSys (see BioCentury, June...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
01:10 , Mar 1, 2014 |  BC Extra  |  Financial News

MorphoSys expects 2014 revenues below 2013

Antibody company MorphoSys AG (Xetra:MOR; Pink:MPSYF) swung to a loss in 4Q13 and said it expects 2014 revenues to be below 2013 figures. The company's 2013 revenues of EUR 78 million ($107.3 million) were up...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

MorphoSys, GlaxoSmithKline deal

MorphoSys granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize its MOR103 program. MorphoSys will receive €22.5 million ($29.3 million) up front and is eligible for up to €423 million ($549.9 million) in milestones,...
07:00 , Jun 10, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) gained $0.24 to $19.79 on Friday after partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a Type II variation application to EMA to expand the European label of Rienso ferumoxytol to...
02:56 , Jun 4, 2013 |  BC Extra  |  Company News

MorphoSys licenses MOR103 to GSK

MorphoSys AG (Xetra:MOR; Pink:MPSYF) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to develop and commercialize MOR103. MorphoSys will receive EUR 22.5 million ($29.3 million) up front and is eligible for up to EUR 423...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Value reality check

Europe's economic crisis has created a new reality. Austerity measures at the national level have placed an even higher premium than in the past on controlling healthcare costs, resulting in an increasingly tough reimbursement environment...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they hope...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Subcutaneous MOR103: Phase I data

A Phase I trial in 32 healthy volunteers showed that single doses of 0.5, 1 and 2 mg/kg subcutaneous MOR103 were well tolerated and had "high neutralizing potency" comparable to a single 2 mg/kg dose...